by 
Porcine vaccines are biological preparations aimed at stimulating the immune system of pigs against specific infectious diseases. They help prevent diseases such as porcine parvovirus, swine erysipelas, porcine circovirus, mycoplasma, and foot-and-mouth disease among pigs. The growing threat of swine diseases and economic losses incurred due to outbreaks has fueled the demand for effective disease prevention through vaccination. Porcine vaccines aid livestock farmers in ensuring the health of pig populations reared for meat production. Common porcine vaccines comprise killed vaccines or live attenuated vaccines designed to trigger an immune response against targeted pathogens in pigs. The global porcine vaccines market offers a wide array of conventional as well as modern recombinant vaccines to choose from for disease protection in commercial pig farms.
The global Porcine Vaccines Market is estimated to be valued at US$ 2.4 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the porcine vaccines market is the rise of novel recombinant vaccine technologies. Traditionally, porcine vaccines were produced through inactivation or attenuation of live viruses. However, the advent of sophisticated genetic engineering tools has enabled manufacturers to develop subunit and recombinant porcine vaccines with superior safety and efficacy profiles. Recombinant vaccines contain specific antigenic proteins that stimulate immune responses without containing entire infectious agents. They have minimal risks of reversion to virulence or transmission of other pathogens. Leading players are focusing on recombinant vaccine R&D to prevent major revenue-draining swine diseases and expanding their product portfolios. Furthermore, advancements in vaccine adjuvant technologies aimed at enhancing immunogenicity with lower antigen quantities per dose are contributing to addressing the challenges around expensive livestock immunization programs globally.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the porcine vaccines market is moderate as it requires significant capital investment and established distribution channels.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of several vendors and availability of substitutes.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as vendors can easily switch to alternative suppliers.
Threat of new substitutes: The threat of new substitutes is moderate as vaccine production requires advanced R&D infrastructure and regulatory approvals.
Competitive rivalry: The competitive rivalry in the porcine vaccines market is high owing to the presence of established global and domestic players.
Key Takeaways
The global porcine vaccines market is expected to witness high growth over the forecast period. The global Porcine Vaccines Market is estimated to be valued at US$ 2.4 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030.
Regional analysis: The Asia Pacific region dominates the global porcine vaccines market owing to rising pork demand from countries like China and Vietnam. China is the largest producer and consumer of pork globally. Increasing pork imports in countries like Vietnam and Philippines are further driving vaccine adoption in the region.
Key players: Key players operating in the porcine vaccines market are Boehringer Ingelheim, Merck Animal Health, Zoetis, and Elanco. Boehringer Ingelheim offers a wide range of porcine vaccines under the Porphise and Ingelvac brands. Merck Animal Health provides vaccines for various indications like porcine epidemic diarrhea, swine erysipelas and porcine parvovirus.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
